Tumor lysis syndrome in multiple myeloma treated by daratumumab combined with chemotherapy: report of two cases and review of literature

VernacularTitle:达雷妥尤单抗联合化疗治疗多发性骨髓瘤发生肿瘤溶解综合征二例并文献复习
Author: Mingyue CHEN ¹ ; Hongdi ZHANG ; Lin SHEN ; Yanhui XIE
Author Information

1. 复旦大学附属华东医院血液科，上海　200040
Keywords: Multiple myeloma; Tumor lysis syndrome; Daratumumab; Recurrence; Refractory
From: Journal of Leukemia & Lymphoma 2021;30(9):547-549
CountryChina
Language:Chinese
Abstract: Objective:To investigate the clinical safety of daratumumab (DARA) in patients with relapsed/refractory multiple myeloma (MM).Methods:The diagnosis and treatment process of 2 cases of relapsed/refractory MM treated in Huadong Hospital of Fudan University in 2020 were retrospectively analyzed, the related laboratory indicators indexes after using DARA were analyzed, and the related literature was reviewed.Results:After using DARA, the 2 patients rapidly developed tumor lysis syndrome (TLS) such as high potassium, high phosphorus, high uric acid, low calcium and kidney damage, which eventually led to the death of patients.Conclusions:Patients with high tumor load treated by DARA are prone to TLS, which is often life-threatening. Clinicians should be alert to the occurrence of such events.